AwesomeCapital
Search This Blog
Friday, November 10, 2023
CymaBay stock spikes ahead of Phase 3 data for lead asset
CymaBay Therapeutics (CYMA) rose 11% on Friday as it prepares to post Phase 3 results for its liver disease therapy seladelpar
https://seekingalpha.com/news/4035202-cymabay-stock-spikes-ahead-phase-3-data-lead-asset
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.